top of page
INSIGHTS
We equip our clients with actionable insights drawn from meticulous analysis of data, firsthand experience, and comprehensive interviews. The contextual evidence we provide enables quick, confident decision-making. We're known for our unique ability to view opportunities and challenges from both the company's and the customer's vantage points, offering a nuanced perspective that can't be found anywhere else.
Filter
Why Biopharma’s Brain Bet Is Moving to Psychiatry
Psychiatry is emerging as the most capital-efficient segment in CNS, attracting major biopharma investment with late-phase assets, validated endpoints, and scalable commercial models. As neurodegeneration remains high-risk, psychiatry offers near-term ROI and strategic fit across the value chain.
Fraol Galan
16 hours ago5 min read
The Evolving Role of In-person vs. Digital Pharma Sales Strategies: Finding the Right Balance
Pharma’s sales model is shifting toward a strategic hybrid: balancing digital convenience with the enduring influence of in-person engagement. While digital channels offer scalable, flexible access, face-to-face interactions remain the most effective for influencing prescribing behavior. The key to success lies in tailoring the right channel to the right context: drug type, physician preference, and market dynamics all matter.
Daniel Yuan
May 284 min read
The Importance of a Harmonized KOL Engagement Strategy
A fragmented KOL engagement approach can damage credibility, strain relationships, and lead to missed insights. This article explores the value of a harmonized strategy that aligns Medical Affairs, Clinical Development, and Commercial teams to ensure consistent, strategic interactions. It also highlights the rise of Digital Opinion Leaders and the need to engage emerging voices. A coordinated approach not only builds trust with experts but also drives better outcomes and long
Federico Somaini
May 193 min read
Shortages and Slowdowns: How Pharmaceutical Tariffs Threaten Supply and Innovation
The Trump administration is doubling down on its promise of pharmaceutical tariffs, designed to re-shore manufacturing and protect strategic interests. What would it mean for biopharma? More importantly, what would it mean for patients? In this article, we summarize existing perspectives and dive into some less-explored topics, such as clinical trial execution, budget management, and early-stage investment.
Liam Boyd
Apr 154 min read
Charting "The Next Frontier" in Medical Device Commercialization: Spinnaker's Perspective in MedTech Strategist
To thrive in today’s evolving healthcare market landscape, medical device companies must take a cohesive, strategic approach to address the complexities and opportunities of the current environment. Success will hinge on aligning commercial models with customer priorities, reducing inefficiencies, and leveraging technology to drive smarter decisions. By Jeremy Cohen, Spinnaker Life Sciences Strategy Consulting.
Jeremy Cohen
Apr 101 min read
Expanding GLP-1s: is Neurology the Next Frontier?
GLP-1 therapies transformed obesity & diabetes care and are now being explored for potential breakthroughs in neurological diseases.
Federico Somaini
Apr 25 min read
bottom of page